Marika Vianello

Treviso, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 04, 2026

Validation of the MOG-AR Score: A Retrospective Multicenter Study.

Validation of the MOG-AR Score: A Retrospective Multicenter Study.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: January 28, 2026

Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.

Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.

Journal: Neurology

Published: November 24, 2025

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

Journal: JAMA network open

Published: November 03, 2025

Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis.

Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis.

Journal: Neurology

Published: September 22, 2025

Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis.

Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: June 19, 2025

Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study.

Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study.

Journal: CNS drugs

Published: May 06, 2025

Multiple sclerosis from onset to secondary progression: a 30-year Italian register study.

Multiple sclerosis from onset to secondary progression: a 30-year Italian register study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: February 02, 2025

Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.

Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.

Journal: Journal of neurology

Published: September 04, 2024

Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.

Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.

Journal: Journal of neurology

Published: April 24, 2024

Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.

Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.

Journal: Journal of neurology

Published: March 25, 2024

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.

Journal: Annals of clinical and translational neurology

Published: March 15, 2024

Showing 1-12 of 30

Last Updated: 09/26/2026